Zacks: Brokerages Expect RA PHARMCTL INC (NASDAQ:RARX) to Post -$0.57 EPS
Brokerages expect RA PHARMCTL INC (NASDAQ:RARX) to report earnings per share of ($0.57) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for RA PHARMCTL INC’s earnings. The company is expected to issue its next earnings results on Thursday, August 10th.
According to Zacks, analysts expect that RA PHARMCTL INC will report full year earnings of ($2.30) per share for the current fiscal year, with EPS estimates ranging from ($2.46) to ($2.14). For the next financial year, analysts forecast that the business will post earnings of ($3.03) per share, with EPS estimates ranging from ($3.55) to ($2.50). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that follow RA PHARMCTL INC.
RA PHARMCTL INC (NASDAQ:RARX) last released its quarterly earnings data on Thursday, May 11th. The company reported ($0.50) EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.08.
A number of research firms recently issued reports on RARX. Zacks Investment Research raised RA PHARMCTL INC from a “hold” rating to a “buy” rating and set a $28.00 price objective for the company in a research report on Saturday, May 27th. Jefferies Group LLC reissued a “buy” rating and set a $25.00 price objective on shares of RA PHARMCTL INC in a research report on Friday, July 14th. Finally, Credit Suisse Group reissued an “outperform” rating and set a $19.00 price objective on shares of RA PHARMCTL INC in a research report on Tuesday, April 18th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $27.00.
RA PHARMCTL INC (RARX) traded up 2.94% during trading on Monday, hitting $13.99. The stock had a trading volume of 72,544 shares. RA PHARMCTL INC has a 1-year low of $12.05 and a 1-year high of $27.84. The firm’s market cap is $315.71 million. The firm’s 50 day moving average is $18.15 and its 200 day moving average is $20.50.
In other RA PHARMCTL INC news, major shareholder Bioventures Ltd Novartis sold 9,019 shares of the business’s stock in a transaction dated Thursday, May 18th. The stock was sold at an average price of $25.50, for a total value of $229,984.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders sold 208,880 shares of company stock valued at $4,946,431 in the last ninety days. Insiders own 14.50% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. Russell Investments Group Ltd. boosted its position in RA PHARMCTL INC by 136.7% in the second quarter. Russell Investments Group Ltd. now owns 49,583 shares of the company’s stock valued at $929,000 after buying an additional 28,632 shares in the last quarter. Goldman Sachs Group Inc. acquired a new position in RA PHARMCTL INC during the first quarter valued at $1,455,000. VHCP Management II LLC boosted its position in RA PHARMCTL INC by 33.6% in the first quarter. VHCP Management II LLC now owns 725,029 shares of the company’s stock valued at $15,436,000 after buying an additional 182,529 shares in the last quarter. Geode Capital Management LLC boosted its position in RA PHARMCTL INC by 8.5% in the first quarter. Geode Capital Management LLC now owns 70,863 shares of the company’s stock valued at $1,508,000 after buying an additional 5,522 shares in the last quarter. Finally, TIAA CREF Investment Management LLC boosted its position in RA PHARMCTL INC by 97.0% in the first quarter. TIAA CREF Investment Management LLC now owns 7,837 shares of the company’s stock valued at $167,000 after buying an additional 3,859 shares in the last quarter. 61.94% of the stock is owned by institutional investors and hedge funds.
RA PHARMCTL INC Company Profile
Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for RA PHARMCTL INC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RA PHARMCTL INC and related companies with MarketBeat.com's FREE daily email newsletter.